Esperion Therapeutics - ESPR Stock Forecast, Price & News

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Esperion Therapeutics Stock Up 3.6 %

Shares of ESPR Stock opened at $6.64 on Friday. The business's fifty day moving average price is $6.15 and its 200 day moving average price is $5.36. Esperion Therapeutics has a 1-year low of $3.28 and a 1-year high of $14.78.

Esperion Therapeutics (NASDAQ:ESPR - Get Rating) last released its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.95) by ($0.10). The firm had revenue of $18.80 million for the quarter, compared to analyst estimates of $18.62 million. During the same quarter in the previous year, the company earned ($1.67) EPS. Esperion Therapeutics's revenue was down 53.8% on a year-over-year basis. As a group, equities research analysts anticipate that Esperion Therapeutics will post -3.79 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. JPMorgan Chase & Co. upgraded Esperion Therapeutics from an "underweight" rating to a "neutral" rating and set a $6.00 target price on the stock in a research report on Wednesday, May 4th. Cowen reduced their target price on Esperion Therapeutics to $13.00 in a research note on Tuesday. Credit Suisse Group lowered shares of Esperion Therapeutics from a "neutral" rating to an "underperform" rating and cut their price target for the stock from $7.00 to $6.00 in a report on Wednesday, August 3rd. Finally, Morgan Stanley increased their price objective on shares of Esperion Therapeutics from $5.00 to $7.00 and gave the company an "underweight" rating in a report on Friday, July 15th. Four investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Esperion Therapeutics has a consensus rating of "Hold" and a consensus price target of $19.90.

Insider Activity at Esperion Therapeutics

In other Esperion Therapeutics news, CEO Sheldon L. Koenig purchased 8,606 shares of Esperion Therapeutics stock in a transaction on Friday, August 5th. The shares were purchased at an average cost of $5.80 per share, with a total value of $49,914.80. Following the completion of the transaction, the chief executive officer now directly owns 198,771 shares in the company, valued at approximately $1,152,871.80. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Joanne M. Foody sold 3,901 shares of the business's stock in a transaction dated Tuesday, July 19th. The stock was sold at an average price of $6.55, for a total value of $25,551.55. Following the completion of the sale, the insider now directly owns 109,077 shares of the company's stock, valued at $714,454.35. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Sheldon L. Koenig purchased 8,606 shares of Esperion Therapeutics stock in a transaction dated Friday, August 5th. The stock was acquired at an average price of $5.80 per share, for a total transaction of $49,914.80. Following the completion of the transaction, the chief executive officer now owns 198,771 shares in the company, valued at approximately $1,152,871.80. The disclosure for this purchase can be found here. Over the last three months, insiders sold 8,905 shares of company stock worth $50,693. 2.40% of the stock is owned by company insiders.